INDEPENDENT INTELLIGENCE
LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Zevra Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERZVRA
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / ZVRA COVERAGE

What’s moving Zevra Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

Investors are testing whether Zevra Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Zevra Therapeutics, Inc. to Report First Quarter 2025 Corporate and Financial Results on May 13, 2025

Zevra Therapeutics, Inc. to Report First Quarter 2025 Corporate and Financial Results on May 13, 2025

The story matters when it changes Zevra Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript

Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript

Investors are testing whether Zevra Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Zevra Therapeutics, Inc. to be Added to Nasdaq Biotechnology Index Effective December 23, 2024

Zevra Therapeutics, Inc. to be Added to Nasdaq Biotechnology Index Effective December 23, 2024

The story matters when it changes Zevra Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2024 Earnings Call Transcript

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2024 Earnings Call Transcript

Investors are testing whether Zevra Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest ZVRA filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-06 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-05 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-09 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-05 · Period 2026-06-04SEC ↗8-KMaterial company eventFiled 2026-05-06 · Period 2026-05-06SEC ↗8-KMaterial company eventFiled 2026-03-16 · Period 2026-03-12SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-20 · Period 2026-06-04SEC ↗SCHEDULE 13GOfficial SEC filingFiled 2026-07-31SEC ↗
EARNINGS / QUARTERLY TRACKER

Zevra Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.